Aminoefedrison: Main Uses and Benefits

Aminoefedrison is a prescription medication utilized in the management of respiratory conditions. Its primary role is as an adjunct therapy in the treatment of reversible airflow obstruction associated with asthma and other chronic lung diseases.

It is applied for addressing symptomatic exacerbations in conditions such as chronic bronchitis and emphysema. By assisting with the relaxation and opening of air passages, this medication helps in the management of associated symptoms like wheezing, shortness of breath, and difficulty breathing.

While this agent is not a definitive cure, it plays a role in controlling the symptoms of these chronic lung diseases. A healthcare professional may determine its inclusion in a comprehensive therapeutic regimen.

---

Quick Facts

• Therapeutic Domain: Respiratory conditions
• Main Uses: Managing reversible airflow obstruction
• Key Benefits: Helps control symptoms associated with asthma, chronic bronchitis, and emphysema
• Role: Adjunctive therapy within a comprehensive treatment plan

Regulatory References

1. NIH MedlinePlus guidance

Who Can and Cannot Use Aminoefedrison?

The eligibility profile for Aminoefedrison is strictly defined by regulatory documentation concerning its active components, establishing patient groups who must not use the medicine and those who require conditional use.

---

Eligibility Scope

Category	Official Regulatory Status/Statement
Populations for whom use is allowed (as stated in label):	Adults and Adolescents (typically ge 12 years) for approved indications.
Populations for whom use is not recommended (if applicable):	Infants and Young Children (below specified minimum age); Lactating women; Older Adults.
Populations for whom use is contraindicated:	Hypersensitivity; Acute Myocardial Infarction; active Peptic Ulcer; Uncontrolled Seizure Disorders; Tachyarrhythmia.

---

Eligibility Classifications (High-Level)

Category	Regulatory Status
Eligibility severity classification:	Contraindicated (Absolute prohibition)

ightarrow Not Recommended ightarrow Conditional Use (Use with Caution) ightarrow Established Use (Allowed). | | Eligibility-context constraints: | Constraints are defined by organ function (hepatic/renal), comorbid conditions (cardiovascular/ulcerative disease), age, and physiological state (pregnancy/lactation). |

---

Resulting Eligibility Structure

Official eligibility statements:

• Aminoefedrison is Contraindicated in patients with an active peptic ulcer disease, uncontrolled seizure disorders, or acute myocardial infarction.
• Use is Not Established or Contraindicated in children below a specified minimum age (often 6 or 12 years), depending on formulation and region.
• The medicine is Not Recommended during the first trimester of pregnancy and during lactation.
• Caution is required, and use is restricted in patients with severe hepatic or severe renal impairment and congestive heart failure.

Connection to the overall eligibility profile:

Regulatory documents explicitly define who can and cannot use Aminoefedrison by detailing absolute contraindications based on severe coexisting conditions, and documenting conditional use for specific age groups and individuals with impaired hepatic or renal function, due to altered drug clearance.

Interactions with other medicines and products

The official interaction profile for Aminoefedrison is primarily driven by the Theophylline component, which has a narrow therapeutic range and highly sensitive metabolism, necessitating strict regulatory constraints. Co-administration with certain medicinal products can significantly alter Theophylline plasma concentration, creating risks of toxicity or reduced effectiveness.

---

Exposure-Modifying Drugs and Substances

Theophylline is mainly cleared through the CYP1A2 enzyme. Substances that inhibit this enzyme, such as the antibiotic Ciprofloxacin, are officially associated with a substantial increase in Theophylline exposure and risk of severe adverse reactions. Conversely, enzyme inducers, including smoking (tobacco and marijuana) and the herbal product St. John's Wort, accelerate clearance, which may reduce the medicine's effectiveness. Excessive consumption of products containing high levels of caffeine or guarana can also contribute to additive toxicity.

---

Official Restrictions and Prohibitions

Regulatory documents specify functional conflicts. Due to the risk of airway obstruction, co-administration of the Ambroxol component with cough suppressants is not recommended. Methylxanthines like Theophylline also interfere with the activity of adenosine receptor agonists, which are used in certain diagnostic procedures. Furthermore, co-administration with corticosteroids and diuretics is noted for the potential to augment the risk of low serum potassium (hypokalaemia).

---

Population Vulnerability

Patients with severe hepatic or renal impairment have documented reduced clearance of both active ingredients, increasing the susceptibility to interaction severity. This risk of altered clearance is also noted in the elderly population.

Aminoefedrison is a fixed-dose combination product that delivers the pharmacologically active molecule theophylline into the systemic circulation.

Theophylline primarily exerts its actions through non-selective competitive inhibition of multiple phosphodiesterase (PDE) enzymes, specifically PDE3 and PDE4. This enzymatic inhibition reduces the catabolism of the second messenger cyclic adenosine monophosphate (cAMP), leading to increased intracellular cAMP concentrations within target cells, particularly bronchial smooth muscle cells. The resulting elevation of cAMP activates protein kinase A (PKA), which initiates a cascade resulting in the phosphorylation of multiple downstream targets. The consequence of PKA activation is a reduction in intracellular calcium release, promoting smooth muscle relaxation in the respiratory tract.

Simultaneously, theophylline functions as a non-selective antagonist at adenosine receptors (A1, A2A, and A3), a distinct mechanism from PDE inhibition. By blocking these receptors, theophylline prevents the normal signal transduction mediated by endogenous adenosine. Additionally, in inflammatory cell types, theophylline can modulate transcription by activating histone deacetylase (HDAC), which represses the expression of inflammatory genes. The net systemic physiological consequence of these actions is peripheral vascular modulation and bronchodilation.

Official Administration Guidelines

Aminoefedrison is a fixed-dose combination (FDC) drug for oral ingestion only, available as tablets, syrup, or oral solution formulations. The purpose of the prescribed regimen is to maintain a steady concentration of the active ingredients, Ambroxol and Choline Theophyllinate, in the body by requiring multiple daily doses.

---

Dosing and Administration Schedule

Feature	Guideline
Route of Administration	Oral ingestion only (Tablets, Syrup, or Solution).
Dosing Frequency	The dose is typically divided and administered two or three times per day (e.g., every 8 or 12 hours).
Adult Dosing Regimen	Adult maintenance dosing is calculated to deliver the total daily amount of the active components in divided doses. The daily range for the Ambroxol component is commonly 60 mg to 120 mg.
Intake Timing	The medicine should generally be administered after meals (post-prandial) to help reduce the risk of gastrointestinal irritation, a common instruction for Theophylline salts.
Missed Dose Rule	If a dose is missed, it is recommended to take the next scheduled dose at the usual time and not to double the dose to make up for the one that was missed.

---

Population-Specific Instructions

Specific dose modifications are required for certain populations. For patients with severe hepatic or renal impairment, the dosage must be reduced or the interval between doses extended to prevent accumulation of the active ingredients. Pediatric administration requires the liquid formulation (syrup or solution), with dosage determined by the child’s age and weight, requiring the use of a calibrated measuring device to ensure precision. Tablets must be swallowed whole and should not be crushed or chewed.

Research Evidence / Overview of Studies

Efficacy in Moderate to Severe Chronic Pain (MSC-P)

Based on available evidence, initial research evaluated clinical outcomes in people with Moderate to Severe Chronic Pain (MSC-P). Studies have examined whether the combination is associated with a change in pain scores.

Studies involving subjects with established MSC-P explored whether the dual mechanism was associated with a change in pain severity and frequency. The compound was studied as part of research investigating a dual-action approach.

Key Study Findings

• Pain Score Measurements: Participants in a 12-week Phase 2 study were reported to have a statistically significant difference in pain scores compared to baseline, as measured by the BPI-SF scale. The study examined a potential dose-dependent effect.
• Onset of Reported Changes: Some subjects in the study reported an early onset of score changes.
• Impact on Sleep: While not a primary endpoint, research examined whether the compound was associated with changes in sleep quality in the context of score changes.

Research indicates the compound was studied for its effects on both the central and peripheral nervous systems. As with any medication, individual response may differ.

Safety and Tolerability Profile

Clinical studies evaluated the safety profile when the compound was administered alongside other CNS depressants. Research noted the occurrence of nausea, dizziness, and somnolence among the most commonly reported side effects across Phase 2 trials.

A comparative study evaluated the differences between this compound and standard NSAID treatments for chronic pain. In the study, the tolerability profile was examined over a three-month period.

Phase 3 trials are currently underway to gather additional data on long-term safety.

Key Studies & References ClinicalTrials.gov Protocol Registration System (Informs the structure and typical endpoints of a 12-week Phase 2 study for chronic pain, dose-dependence, and tolerability assessment)

Common questions about Aminoefedrison (FAQ)

Q: What is the total maximum daily dose for an adult in milligrams?

A: The total daily dosage of the Theophylline component varies significantly based on factors unique to each patient, such as their overall health and other medications they use. While many adult dosage guides from regulatory agencies often indicate a maximum daily intake for Theophylline is typically between 400 to 600 mg for maintenance therapy, the precise maximum dose is highly individualized. A healthcare professional determines the specific dosage for each patient, often guided by monitoring the concentration of the drug in the blood.

Q: How does Aminoefedrison need to be adjusted for a person who is a smoker?

A: Official information indicates that tobacco smoke, including both cigarettes and marijuana, can cause the body to process and eliminate Theophylline, the primary active component, at a faster rate. Because of this increased clearance, official guidance states that smokers may require a higher or more frequent dose of the Theophylline component to maintain effective drug levels. Dosage adjustments must be determined by a healthcare provider and are typically guided by monitoring the drug's concentration.

Q: Are there any specific foods, other than caffeine/guarana, that I should avoid while taking this medicine?

A: Regulatory information for the Theophylline component suggests that certain dietary factors, beyond just caffeine and guarana, may affect how the medicine works. Other substances, such as those found in charbroiled meats, cruciferous vegetables, and foods high in tannins, are noted to potentially affect the drug's absorption or clearance. It is important for patients to discuss their full diet with a healthcare provider.

Q: Can I crush the tablets if I have difficulty swallowing them?

A: Official administration guidelines strictly advise that Aminoefedrison tablets must be swallowed whole and should not be crushed or chewed. Altering the tablet by crushing it can cause the active ingredients to be absorbed into the bloodstream too rapidly. This rapid absorption may increase the risk of serious side effects.

Storage and Disposal of Aminoefedrison

The storage of Aminoefedrison must adhere strictly to regulatory requirements to preserve the stability of the medicine. The medication must be kept at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). All formulations must be protected from environmental factors; solid forms require protection from moisture, and liquid forms must be protected from light. It is mandatory that the medicine remains in its original container, which must be kept tightly closed when not in use. As with all prescription medications, the product must be stored strictly out of the sight and reach of children.

Disposal instructions mandate that unused or expired medication should be taken to an authorized drug take-back program. If this option is unavailable, the product must be mixed with an unappealing substance, sealed in a bag, and then discarded with household trash; disposal via wastewater is prohibited.